SAN FRANCISCO – Imaging giant GE Healthcare is slated to spinoff from its parent company in an IPO. It reportedly filed confidentially with the SEC in mid-December and is slated to make its independent public debut in mid-2019. (See BioWorld MedTech, June 27, 2018.) Given this, the company opted to update investors at the J.P. Morgan Healthcare conference, although it avoided any discussion of the public offering or detailed financials.

SAN FRANCISCO – The name of the game thus far for Guardant Health Inc. has been precision medicine, using genomics to select the best therapy particularly for advanced cancer patients. But it's moving further into cancer recurrence monitoring – and even, ultimately, the Holy Grail of a liquid biopsy for cancer screening.